HIV comorbidities increase in US as patients age
Comorbidities are common among the aging HIV population in the United States and have increased over time, researchers wrote in The Journal of Infectious Diseases. Previous research has demonstrated similar increases in comorbidities.
“As the HIV-infected population ages, it is becoming increasingly important to identify and manage comorbidities that may increase the risk of cardiovascular complications, kidney disease, osteoporosis and bone fracture,” researcher Joel E. Gallant, MD, MPH, medical director of specialty services at the Southwest CARE Center in Santa Fe, New Mexico, and colleagues wrote. “The comorbidities will influence the choice of ART and are thus an important consideration in optimizing the selection of HIV treatment.”
To gauge the prevalence of comorbidities in the United States, the researchers viewed health care claims recorded in databases for commercial, Medicaid and Medicare payers between 2003 and 2013. Among patients with HIV, they identified 36,298 with commercial coverage, at a mean age of 42.2 years; 26,246 on Medicaid with a mean age of 41.6 years; and 1,854 on Medicare with a mean age of 71.5 years. Up to three control patients without HIV were matched to each patient with HIV.
The most common comorbidity among those with HIV was essential hypertension, affecting 31.4%, 39.3% and 76.2% of patients on commercial, Medicaid and Medicare coverage, respectively. That was followed by hyperlipidemia, endocrine disease, diabetes and renal impairment.
The researchers noted significant increases in comorbidities among patients with HIV between 2003 and 2013. In that period, among HIV patients with commercial coverage, the proportion with hypertension rose from 11.6% in 2003 to 25% in 2013. Those with hyperlipidemia rose from 9.5% to 21.9%, and those with diabetes rose from 6.4% to 9.4%. Among patients with HIV on Medicaid, those proportions increased from 16.6% to 48.2%, 7.1% to 27.3% and 8.7% to 19.4%, respectively. Among those with HIV on Medicare, rates increased from 34.2% to 65.1%, 12.1% to 47.5% and 20.4% to 31.1%, respectively.
In all three payer groups, five comorbidities — deep vein thrombosis, hepatitis C, renal impairment, thyroid disease and liver disease — were significantly more prevalent among patients with HIV than among the control patients, the researchers said.
One of the starker contrasts was found in the proportion of patients with hepatitis C among those on Medicaid. According to the researchers, 22.9% of those with HIV were also infected with HCV, compared with 3.7% of those without HIV.
“Clinically, while older age by itself contributes to the increased occurrence of comorbidities, underlying HIV infection and its treatment are also important variables,” Gallant and colleagues wrote. “HIV infection may result in metabolic complications, renal toxicity, hepatotoxicity, and osteoporosis. Similarly, depending on the ART regimen used, side effects can include lipodystrophy, nephrotoxicity, hepatotoxicity, bone loss, and increased risk of [cardiovascular] events.”
In related commentary, Marc van der Valk, MD, PhD, and Peter Reiss, MD, PhD — both of the Amsterdam Infection and Immunity Institute in the Netherlands — wrote that clinicians must respond to the increasing rate of comorbidities among patients with HIV by shifting their focus.
“These patients are experiencing an increasing burden of aging-related noncommunicable diseases (NCDs),” they wrote. “HIV health care providers, including infectious diseases clinicians, therefore need to increasingly transition from a focus on sustaining HIV suppression and immune restoration to a focus on managing and preventing NCDs.”
van der Valk and Reiss pointed out that Gilead Sciences supported the study by Gallant and colleagues, and they argued that more nonpharmaceutical entities should begin supporting research on the costs associated with HIV comorbidities.
“We would rather urge policymakers, insurance companies and research agencies to structurally support and undertake this type of research in close collaboration with all relevant stakeholders, including pharmaceutical companies, in the field,” they wrote. “This will contribute to an improved and cost-effective integration of prevention and management of chronic noncommunicable comorbidities in our HIV care systems and, thereby, increase the long-term quality of life and resilient aging of our patients.” – by Joe Green
Disclosures: Gallant reports that he has received research funding from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, Sangamo BioSciences and ViiV Healthcare/GlaxoSmithKline. He also reports receiving consulting fees from Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, Theratechnologies and ViiV Healthcare/GlaxoSmithKline. Please see the study and commentary for all other authors’ relevant financial disclosures.